SBI Securities’s BioAtla BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.1K Buy
267
+45
+20% +$191 ﹤0.01% 2771
2026
Q1
$1.79K Buy
222
+46
+26% +$538 ﹤0.01% 2459
2025
Q4
$4.99K Buy
176
+27
+18% +$1.06K ﹤0.01% 2024
2025
Q3
$5.13K Buy
149
+29
+24% +$670 ﹤0.01% 2035
2025
Q2
$2.38K Buy
120
+38
+46% +$771 ﹤0.01% 2315
2025
Q1
$1.43K Buy
82
+65
+382% +$1.39K ﹤0.01% 2437
2024
Q4
$488 Buy
+17
New +$1.43K ﹤0.01% 2896

SBI Securities's BCAB Position: Q2 2026 in Review

SBI Securities increased its BioAtla (BCAB) stake by 20% in Q2 2026, buying an estimated $191 and bringing the position to 267 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

SBI Securities first reported a position in BCAB in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.13K in Q3 2025. 1 fund tracked by Wall St. Rank holds BCAB as of Q2 2026.

  • SBI Securities held 267 shares of BioAtla worth $1.1K as of Q2 2026.
  • SBI Securities bought 45 BioAtla shares in Q2 2026, an estimated $191.
  • BioAtla made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2771 holding.
  • SBI Securities first reported a position in BioAtla in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's BioAtla position peaked at $5.13K in Q3 2025.
  • 1 fund tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.